Jacobio Pharmaceuticals Group Co., Ltd. stock analysis
Want to see HK:1167 full AI Analyst Report?
Relatively low debt compared with equity gives Jacobio more balance-sheet flexibility than a highly leveraged biotech. This can help preserve strategic options for clinical development and operations, although the benefit is moderated by declining equity and continued losses.
A focused oncology pipeline built around targeted small molecules gives Jacobio a defined scientific strategy and the potential to address specific molecular pathways. If clinical candidates advance, this specialization can support partnering opportunities and future product value.
Strong gross margins in recent periods indicate that the company’s underlying revenue streams can carry attractive economics before operating and research costs. This provides a potentially useful foundation for future earnings improvement if pipeline progress increases revenue without comparable cost growth.
A roughly 74% year-on-year revenue decline is a major setback for a clinical-stage company whose income can depend on partnering and milestone events. Such volatility makes operating planning harder and weakens the near-term base from which sustainable growth must be rebuilt.
Recurring operating and net losses show that current revenue has not covered ongoing research and operating expenditure. Continued negative profitability can reduce financial resilience, limit internally funded development, and increase the importance of successful pipeline advancement or additional financing.
Sustained negative operating and free cash flow means Jacobio is not yet funding its activities from internally generated cash. Higher 2025 burn increases sensitivity to external capital or existing balance-sheet resources and could constrain the pace or breadth of clinical investment.
Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) has issued an announcement. Jacobio Pharmaceuticals reported interim results marked by continued progress in its oncology pipeline, led by glecirasib and sitneprotafib
Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) just unveiled an announcement. Jacobio Pharmaceuticals Group Co., Ltd., a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong, specializes in targeted oncology
Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) has provided an announcement. Jacobio Pharmaceuticals has dosed the first patient in China in a Phase Ib/III clinical trial of its orally
Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) just unveiled an announcement. Jacobio Pharmaceuticals reported that all resolutions at its 5 June 2026 annual general meeting were approved by shareholders
An announcement from Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) is now available. Jacobio Pharmaceuticals has been steadily repurchasing its own shares under an existing mandate, accumulating 7,47,800 treasury
An update from Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) is now available. Jacobio Pharmaceuticals has received a US$100 million upfront payment from AstraZeneca under their license and collaboration
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 6 | 11 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 4 | 0 | 8 |
